Discontinuation Cluster · SNRI
Effexor (Venlafaxine) Onsite Taper
Onsite venlafaxine (Effexor) taper — the SNRI with the most severe withdrawal — bridged with full-spectrum iboga TA.
Generic name
Venlafaxine
Drug class
SNRI
Half-life class
short
Plasma half-life
≈ 5 hours (parent), 11 hours (O-desmethylvenlafaxine)
Typical dose range
37.5–375 mg/day
Onsite taper duration
14–28 days onsite
TA bridge
Iboga TA 75–150 mg BID (sub-psychoactive)
Quick Answer
Can I taper off Effexor (Venlafaxine) at MindScape?
Reviewed by Dr. Arellano, M.D. — May 2026
Withdrawal Profile
- Severe brain zaps within hours of a missed dose
- Dizziness, vertigo, gait instability
- Noradrenergic rebound — sweating, hypertension, tachycardia
- Anxiety crises, panic surges
- GI distress, sleep disruption
Why It's Hard To Taper At Home
- Venlafaxine's short half-life means symptoms emerge between doses, not just on taper.
- The XR formulation is bead-based — patients have to count beads to micro-taper.
- Both serotonergic and noradrenergic withdrawal components — broader receptor coverage required.
- BP and HR rebound on taper requires telemetry that home tapers can't provide.
MindScape Onsite Protocol
- Bead-counting hyperbolic taper or compounded liquid venlafaxine.
- Iboga TA bridge 75–150 mg BID — broader receptor coverage matches dual SNRI footprint.
- Continuous cardiac telemetry with BP and HR monitoring (noradrenergic rebound).
- Magnesium pre-loading; electrolyte normalization.
Day-By-Day Patient Experience
- Days 1–4: workup, magnesium loading, first reduction with strong TA cover.
- Days 5–14: hyperbolic step-downs; brain-zap and BP-spike monitoring.
- Days 15–22: full discontinuation under telemetry.
- Days 23–28: optional ibogaine HCl flood and post-flood tail.
Day-counts and step-cadences are illustrative ranges, not personal medical advice. Individual taper duration is determined onsite by the medical team after baseline workup.
Citations & Reading
- Horowitz MA, Taylor D. (2019). Lancet Psychiatry, 6(6), 538-546.
- Fava GA, et al. (2018). Psychotherapy and Psychosomatics, 87(4), 195-203.
For the broader iboga-TA evidence base, see the 2026 evidence-base review and the onsite taper cohort methodology page.